Allogene Therapeutics presented data from a safety review of patients treated in Phase 1 trials with ALLO-501/501A, showing potential for deep and durable remissions in relapsed and treatment-refractory cancers.
AI Assistant
ALLOGENE THERAPEUTICS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.